Immunotherapy: Open Access
Open Access

Cancer Vaccines: Transforming the Field of Prophylactic Immunotherapy

Andrew Doey^{* *}Correspondence: Andrew Doey, Department of Immunology, Aston University, Birmingham, United Kingdom, Email:

Author info »

Description

Cancer vaccines have significant attention as a innovative solution in the fight against cancer. These vaccines have the potential to transform the way we approach cancer treatment, not only by targeting established cancers but also by preventing them from developing in the first place. While cancer vaccines are still an area of active research, their ability to enhance the immune system's ability to recognize and fight cancer cells makes them an exciting frontier in cancer care. This article describes the role of cancer vaccines in clearing the path for prophylactic immunotherapy-immunotherapy aimed at preventing cancer. Cancer vaccines can be broadly divided into two categories.

Therapeutic vaccines: These vaccines are designed to treat existing cancer by stimulating the immune system to recognize and attack cancer cells. Unlike preventive vaccines, therapeutic vaccines target cancer-specific antigens-proteins or molecules that are found on the surface of cancer cells but not normal cells. They essentially train the immune system to recognize and destroy cancer cells more effectively.

Prophylactic vaccines: These vaccines aim to prevent cancer from developing in the first place by stimulating the immune system to recognize and destroy cancer-related pathogens or abnormal cells before they can lead to cancer. Prophylactic vaccines are typically given to individuals who are at a high risk for certain types of cancer, such as those with a genetic predisposition or those exposed to cancer-causing viruses.

Prophylactic cancer vaccines

The most significant success of prophylactic cancer vaccines has been seen in the development of vaccines against Human Papillomavirus (HPV) and the Hepatitis B Virus (HBV), both of which are linked to the development of certain cancers.

HPV vaccines: HPV is a group of viruses that are responsible for a variety of cancers, most notably cervical cancer, but also anal, oropharyngeal and other genital cancers. The development of vaccines against HPV, such as Gardasil and Cervarix, has revolutionized cancer prevention. These vaccines protect against the strains of HPV most commonly associated with cancer development.

Hepatitis B vaccine: The hepatitis B virus (HBV) is a major cause of liver cancer (hepatocellular carcinoma). Chronic HBV infection leads to long-term liver inflammation and increases the risk of developing liver cancer. The hepatitis B vaccine has been shown to effectively prevent HBV infection, thereby reducing the incidence of liver cancer. Since the introduction of the HBV vaccine, there has been a significant decrease in the incidence of liver cancer in populations with high vaccination coverage.

Conclusion

Prophylactic cancer vaccines have the potential to change the landscape of cancer prevention, offering a unique tool for reducing cancer incidence on a global scale. The success of vaccines like those for HPV and HBV proves that cancer can be prevented through vaccination and ongoing research holds the potential of more vaccines targeting a broader range of cancers. While challenges remain, the future of prophylactic cancer immunotherapy is bright, offering new possibilities for preventing cancer and improving public health worldwide. With continued research and global collaboration, cancer vaccines could become a fundamental of preventive healthcare, saving millions of lives in the process.